Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Genetic mutations may drive tumor formation by blurring growth signals

Genetic mutations in a form of non-small cell lung cancer (NSCLC) may drive tumor formation by blurring cells' perception of key growth signals, according to a new laboratory study published August 31, 2018 in Science.

3 Sep 2018

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas.

25 Aug 2018

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Immunovia's new blood-based testing platform accurately detects non-small cell lung cancer

Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray could differentiate healthy controls from non-small cell lung cancer samples with a 95 % accuracy.

14 Aug 2018

Inhibition of NOVA1 gene helps prevent growth of lung cancer tumors

Researchers have identified a gene that when inhibited or reduced, in turn, reduced or prevented human non-small cell lung cancer tumors from growing.

7 Aug 2018

Blood-based test accurately identifies lung cancer patients who could benefit from immunotherapies

Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.

7 Aug 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Targeting amino acid transporter may improve survival rates for non-small cell lung cancer patients

An amino acid transporter named xCT may affect the growth and progression of non-small cell lung cancer, a discovery that may predict the five-year survival rate of patients suffering from this cancer, now at 16 percent, researchers at Georgia State University and Vanderbilt University Medical Center have concluded.

11 Jul 2018

Study explores occurrence and treatment of brain metastases in ROS1 lung cancer

Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.

10 Jul 2018

Researchers find new metabolic vulnerability in small cell lung cancer

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in small cell lung cancer (SCLC) that can be targeted by existing drug therapies.

3 Jul 2018

Scientists discover new kind of small-cell lung cancer

Researchers have discovered a new kind of small-cell lung cancer. The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease.

26 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Researchers discover new method to predict chance of cancer treatment success

Doctors are increasingly fighting cancer by stimulating patients' immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success.

12 Jun 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

HKBU researchers develop metal based probes for imaging dopamine receptors in living cells

A team led by Dr Edmond Ma Dik-lung, Associate Professor of the Department of Chemistry of Hong Kong Baptist University has developed the world's first iridium(III)-based probes for imaging dopamine receptors in living cells.

16 May 2018

Cleveland Clinic researcher wins NCI grant to delve into cancer genetics and radiation effectiveness

Can the genetic makeup of their cancers predict how patients with lung cancer will respond to radiation therapy? And can this information be used to advance a genetically guided strategy for patients with these tumors? Cleveland Clinic researcher and radiation oncologist Mohamed Abazeed, M.D., Ph.D., has been awarded a $2 million grant from the National Cancer Institute (NCI) to delve into those and other related questions.

15 May 2018